Avalyn Pharma Inc. Common Stock (AVLN) - Net Assets
Based on the latest financial reports, Avalyn Pharma Inc. Common Stock (AVLN) has net assets worth $- USD as of . Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($-) and total liabilities ($-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Avalyn Pharma Inc. Common Stock liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Avalyn Pharma Inc. Common Stock - Net Assets Trend (2024–2025)
This chart illustrates how Avalyn Pharma Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Also explore how large is Avalyn Pharma Inc. Common Stock's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Avalyn Pharma Inc. Common Stock (2024–2025)
The table below shows the annual net assets of Avalyn Pharma Inc. Common Stock from 2024 to 2025. For live valuation and market cap data, see AVLN market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-238.66 Million | -36.75% |
| 2024-12-31 | $-174.52 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Avalyn Pharma Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8520400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $26.71 Million | % |
| Total Equity | $-238.66 Million | 100.00% |
Avalyn Pharma Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Avalyn Pharma Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangsu Canlon Building Materials Co Ltd
SHE:300715
|
$1.14 Billion |
|
Tianjin You Fa Steel Pipe Group Stock Co Ltd
SHG:601686
|
$1.14 Billion |
|
Sensirion Holding AG
SW:SENS
|
$1.14 Billion |
|
Feng Hsin Steel Co Ltd
TW:2015
|
$1.14 Billion |
|
Nazara Technologies Limited
NSE:NAZARA
|
$1.14 Billion |
|
Shenzhen Sosen Electronics Co.Ltd.
SHE:301002
|
$1.14 Billion |
|
Bega Cheese Ltd
AU:BGA
|
$1.14 Billion |
|
Lindsay Corporation
NYSE:LNN
|
$1.14 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Avalyn Pharma Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -174,522,000 to -238,656,000, a change of -64,134,000.
- Net loss of 85,204,000 reduced equity.
- New share issuances of 100,363,000 increased equity.
- Other factors decreased equity by 79,293,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-85.20 Million | -35.7% |
| Share Issuances | $100.36 Million | +42.05% |
| Other Changes | $-79.29 Million | -33.22% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Avalyn Pharma Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2024-12-31 | $-4.17 | $28.41 | x |
| 2025-12-31 | $-5.71 | $28.41 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Avalyn Pharma Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-32.29 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-61.34 Million |
Industry Comparison
This section compares Avalyn Pharma Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $161,374,297
- Average return on equity (ROE) among peers: -386.97%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Avalyn Pharma Inc. Common Stock (AVLN) | $- | 0.00% | N/A | $1.14 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $98.20 Million |
| Abcellera Biologics Inc (ABCL) | $1.14 Billion | -12.83% | 0.19x | $1.57 Billion |
| Abeona Therapeutics Inc (ABEO) | $681.00K | -3192.95% | 12.43x | $313.99 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $179.85 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $793.56 Million |
| Arbutus Biopharma Corp (ABUS) | $26.88 Million | -30.41% | 0.07x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $-1.46 Million | 0.00% | 0.00x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $84.98 Million | -24.53% | 0.28x | $3.65 Billion |
About Avalyn Pharma Inc. Common Stock
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled fo… Read more